Media Coverage
Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs
Xconomy
Media Coverage
Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement
ADC Review
Media Coverage
U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a Major Milestone in the Development of BDC-1001
ADC Review
Media Coverage
Randall Schatzman, Ph.D. to Lead Growth of Immune- Stimulating Antibody Conjugates at Bolt Biotherapeutics
ADC Review
Media Coverage
How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy
ADC Review
Media Coverage
Bolt Biotherapeutics Nabs $93.5M to Push Provenge Inventor’s New Idea Deeper in the Clinic
Endpoints News
Media Coverage
Bolt’s Myeloid Twist on ADCs Charged up with $93.5M series C
BioCentury
Media Coverage
Pfizer-Backed Bolt Therapeutics Strikes $93.5M Funding Round As Lead Med Hits the Clinic
Fierce Biotech
Media Coverage
Agonist ecstasy? HER2 (and more) ‘Bolt’-on strategy draws $93.5M series C
BioWorld
Media Coverage
Bolt Biotherapeutics Initiates Immunotherapy Trial of Lead Drug Candidate in HER2-Expressing Solid Tumors
Precision Oncology News